尽管出现亏损，但 Denali Therapeutics 在 2025 年第二季度的收益超出预期，但由于临床进展的持续进展，股价上涨。 Denali Therapeutics beat earnings estimates in Q2 2025 despite a loss, stock rose on continued clinical progress.

Denali治疗学公司(DNLI)报告了2025年的Q2收入,每股损失7.74美元,略微超出估计,以及固定收入。 Denali Therapeutics (DNLI) reported Q2 2025 earnings with a loss of $0.74 per share, slightly beating estimates, and flat revenue. 股票涨至15.02美元,12个月平均价格目标是32.64美元,并获得一致的“Buy”评分。 The stock rose to $15.02, with a 12-month average price target of $32.64 and a consensus "Buy" rating. 该公司的重点是神经退化和淋病储存疾病,继续推进临床和临床前期方案。 The company, focused on neurodegenerative and lysosomal storage diseases, continues advancing clinical and preclinical programs. 8月份内幕出售股票,机构所有权仍然高达92.92%。 Insiders sold shares in August, and institutional ownership remains high at 92.92%.